Gregory Bonfiglio is a prominent figure in the cell and gene therapy (CGT) landscape, serving as the Founder and Managing Partner of Proteus, LLC, an investment and advisory firm established in 2006. Under his leadership, Proteus has become a pivotal player in the CGT industry,...
Gregory Bonfiglio is a prominent figure in the cell and gene therapy (CGT) landscape, serving as the Founder and Managing Partner of Proteus, LLC, an investment and advisory firm established in 2006. Under his leadership, Proteus has become a pivotal player in the CGT industry, offering specialized fund management and consulting services that cater to the unique challenges and opportunities within this rapidly evolving field. Mr. Bonfiglio's extensive expertise in venture capital, technology transfer, and corporate development has enabled Proteus to forge strategic partnerships and drive innovation in the commercialization of groundbreaking therapies.
At Proteus, Mr. Bonfiglio oversees key projects that focus on advancing the development of cell and gene therapies, leveraging his deep understanding of life sciences and cell biology. His role involves providing Board of Director (BOD) services and consulting to emerging companies, helping them navigate the complexities of mergers and acquisitions, patent strategies, and market entry. His insights are invaluable in identifying promising technologies and guiding startups through the commercialization process, ensuring that transformative therapies reach patients in need.
In addition to his work at Proteus, Mr. Bonfiglio serves as a Senior Advisor to ImmuneBridge, Inc., where he contributes his strategic vision to enhance the company’s growth trajectory in the immunotherapy sector. His multifaceted skill set, which includes angel investing and expertise in mergers, positions him as a thought leader in the CGT arena, making significant contributions to the advancement of innovative therapies that have the potential to change lives. Through his endeavors, Gregory Bonfiglio continues to shape the future of cell and gene therapies, driving progress in a field that holds immense promise for patients worldwide.
